[ seh-lank ]

Selank, a peptide labeled as an "anti-anxiety" peptide, has been shown to improve learning, memory, cognition, depression, energy, and alleviate weakness. It has been approved in Russia for the treatment of Generalized Anxiety Disorder (GAD) and as a nootropic, and has no reported negative side effects or risk of addiction.

Developed by combining the sequence of tuftsin, a peptide related to immune function, with a sequence that improves its stability, Selank has been clinically proven to provide sustained nootropic and anxiolytic effects. It has also been shown to improve anxiety, learning, memory, help with brain damage recovery, stabilize enkephalins in the blood, aid in alcohol withdrawal, and prevent weight gain and reduce cholesterol.

Selank can also boost immune function by increasing the release of IL-6 and interferons, both anti-inflammatory and anti-viral molecules. A relative of the nootropic drug Semax, Selank was developed at the Institute of Molecular Genetics in cooperation with the V.V. Zakusov Research Institute of Pharmacology.